MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
Clinical Trials
35
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2008
Completed
27
77.1%
Recruiting
2
5.7%
Terminated
5
14.3%
Withdrawn
1
2.9%
No approval data available
- MediWound's EscharEx VALUE Phase III trial for venous leg ulcers continues enrollment targeting 216 patients, with interim assessment and completion expected by year-end 2026. - The company plans to expand EscharEx development into diabetic foot ulcers and pressure ulcers in 2026 following positive regulatory feedback from FDA and EMA. - NexoBrid manufacturing facility expansion is now fully operational with sixfold increased production capacity, positioning the company for anticipated regulatory approvals in 2026. - MediWound reported $17 million in 2025 revenue and updated guidance projecting growth to $24-26 million in 2026, $32-35 million in 2027, and $50-55 million in 2028.
- MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs). - The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients. - EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment. - An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.
